1215176-91-2

Upstream product

• 83-87-4 penta-O-acetyl-α-D-galactopyranose 
• 1152-39-2 p-methylphenyl-1-thio-β-D-galactopyranoside 
• 28244-94-2 4-methylphenyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactopyranoside 
• 106-45-6 para-thiocresol 
• 824-94-2 p-methoxybenzyl chloride 

Downstream Products

• 1215176-93-4 4,6-O-isopropylidene-2,3-di-O-4-methoxybenzyl-α-D-galactopyranose 
• 1215176-98-9 C₂₇H₃₂Cl₃NO₈ 
• 1215176-94-5 (2S,3S,4R)-2-hydroxy-3,4-O-isopropylidene-11-octadecyn-1-yl 4,6-O-isopropylidene-2,3-di-O-(4-methoxybenzyl)-α-D-galactopyranoside 
• 1215176-95-6 (2S,3R,4R)-2-hexacosanoyloxy-3,4-O-isopropylidene-11-octadecyn-1-yl 4,6-O-isopropylidene-2,3-di-O-(4-methoxybenzyl)-α-D-galactopyranoside 
• 1143983-18-9 2,3-bis-O-(4-methoxyphenylmethyl)-4,6-O-(4-methoxyphenylmethylidene)-α-D-galactopyranosyl trichloroacetimidate 

Relevant academic research and scientific papers

Efficient Divergent Synthesis of New Immunostimulant 4″-Modified α-Galactosylceramide Analogues

A synthesis strategy for the swift generation of 4″-modified α-galactosylceramide (α-GalCer) analogues is described, establishing a chemical platform to comprehensively investigate the structure-activity relationships (SAR) of this understudied glycolipid

ESTERIFIED ALPHA-GALACTOSYLCERAMIDE

The present invention provides novel esterified α-galactosylceramides effective for cancer treatment and the like, and a medicament containing same. The present invention relates to a compound represented by the formula (I): wherein R1 is a hyd